Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Erectile Dysfunction Drugs Market to Reach US$ 2.5 Bn by 2028, Says TMR Study

This image opens in the lightbox

News provided by

Transparency Market Research

14 Apr, 2022, 16:30 GMT

Share this article

Share toX

Share this article

Share toX

 - Pharmaceutical companies in erectile dysfunction (ED) drugs market witnessing vast avenues in generic versions, underpinned by key drugs losing their patent

 - Promotional and awareness campaigns along with patient education to spur revenue generation; North America highly lucrative market, fueled by high prevalence of ED

ALBANY, N.Y., April 14, 2022 /PRNewswire/ -- Pharmaceutical companies in the erectile dysfunction drugs market have reaped massive sales revenues on the back of widespread patient education about the treatment options for the condition. Over the past few decades, the utilization of oral phosphodiesterase type 5 inhibitors in ED drugs has propelled the revenue growth. The global valuation of the erectile dysfunction (ED) drugs market is projected to reach US$ 2.5 Bn by 2028.

Extensive use of cialis (tadalafil) and levitra/staxyn (vardenafil) in the patient population has spurred profitable opportunities in the erectile dysfunction (ED) drugs market. The demand for drug for the treatment of ED in elderly population has bolstered new revenue streams in recent years.

Extensive R&D by pharmaceutical and branded drugs manufacturers on pharmacological response test for erectile dysfunction are extending the horizon, finds TMR analysts in an in-depth report on the erectile dysfunction (ED) drugs market. Over the years, insurance coverage for the patient population has been reduced, thus impacting the growth opportunities for drug manufacturers.

Request Brochure of Erectile Dysfunction (ED) Drugs Market Research Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1550

Furthermore, a number of blockbuster patent expirations have gone off patent since the beginning of this decade. The trend has opened a new avenue for generic drug manufacturers, assert the authors of the study on the erectile dysfunction (ED) drugs market.

Key Findings of Erectile Dysfunction (ED) Drugs Market Study

  • Global Prevalence of ED Reinforces Treatment Innovations: The increasing prevalence of erectile dysfunction has propelled the adoption of medication drugs. The prevalence of the problem has increased on the back of the rapidly aging population in developing and developed economies. Pharmaceutical companies have been leveraging the synergistic abilities of mergers & acquisitions and research collaborations. This has nudged drug manufacturers to continue developing novel medications. Ongoing clinical trials will pave the way to innovative medications for ED.
  • Growing Product Approvals in Key Regions Invigorates Revenue Potential: Drug manufacturers are keen on improving the safety and efficacy of drugs in the newly launched medications. A proper understanding of psychological and organic causes of ED will enrich the revenue potential of the erectile dysfunction (ED) drugs market. In developed nations, notably the U.S., have in recent years witnessed approval of new drugs, and thus, has offered impetus to the expansion of the erectile dysfunction (ED) drugs market.
  • Loss of Patent Exclusivity of Branded Drugs to Turn Attention Toward Generics: In recent years, loss of patent exclusivity of key drugs in the erectile dysfunction (ED) drugs market has broadened the scope of commercialization of generic drugs in the erectile dysfunction (ED) drugs market. Major pharmaceutical companies are keen on tapping into the emerging revenue streams and increase their generic drug pipeline.

Request for Analysis of COVID-19 Impact on Erectile Dysfunction (ED) Drugs Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1550

Erectile Dysfunction (ED) Drugs Market: Key Drivers

  • Prevalence of ED in men above 40 years is a key driver of the erectile dysfunction (ED) drugs market. ED has been frequently associated with considerable emotional and psychological consequences on the quality of life of the patient. This has been driving the impetus for the various treatment options worldwide.
  • Growing awareness about the numerous risk factors of ED, such as hypertension, cardiovascular disease, diabetes mellitus, and hyperlipidemia will spur innovations in the erectile dysfunction (ED) drugs market

Erectile Dysfunction (ED) Drugs Market: Regional Growth Dynamics

  • North America held a major share of the global the erectile dysfunction (ED) drugs market in 2020. The U.S. and Canada have contributed sizable share of revenues to this regional market, propelled by widespread intake of ED drugs for treatment among the patient population.
  • Asia Pacific is another lucrative region in the global erectile dysfunction (ED) drugs market. Rise in patient education about the risk factors and awareness about the treatment options have reinforced the adoption of products.

Get Exclusive PDF Sample Copy of Erectile Dysfunction (ED) Drugs Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1550

Erectile Dysfunction (ED) Drugs Market: Key Players

Some of the key players in the erectile dysfunction (ED) drugs market are Teva Pharmaceutical Industries Ltd., Vivus, Inc., Bayer AG, Eli Lilly and Company, Dong-A ST Co., Ltd., and Pfizer, Inc.

Global Erectile Dysfunction (ED) Drugs Market: Segmentation

Erectile Dysfunction (ED) Drugs Market, by Drug

  • Viagra
  • Cialis
  • Staxyn/Levitra
  • Stendra/Spedra
  • Others

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1550

Erectile Dysfunction (ED) Drugs Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Erectile Dysfunction (ED) Drugs Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of Middle East & Africa

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Industry Research Reports by Transparency Market Research:

Erectile Dysfunction Shockwave Therapy Market: The global erectile dysfunction shockwave therapy market is driven by high prevalence and rise in incidence rate of erectile dysfunction across the globe. According to an independent survey, it is estimated that around 30 million men in the U.S. are affected by erectile dysfunction.

Erectile Dysfunction Treatment Devices Market: The global erectile dysfunction treatment devices market is projected to be primarily driven by the high prevalence and rising incidences of erectile dysfunction. Around 50% of men aged 40 to 70 years are estimated to suffer from some degree of erectile dysfunction.

Pelvic Floor Electrical Stimulation Devices Market: The market growth is primarily driven by the increasing prevalence of urinary incontinence among women worldwide, surge in the number of players manufacturing pelvic floor electrical stimulation devices, research and development activities, positive response from the FDA, and growing demand for pelvic floor electrical stimulation devices due to increase in public awareness and physiotherapist recommendations.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact :
Rohit Bhisey

Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Follow Us: Twitter | LinkedIn
Blog: https://tmrblog.com
Browse PR - https://www.transparencymarketresearch.com/pressrelease/erectile-dysfunction-drugs.htm

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.